The Bank of New York Mellon Corporation (NYSE:BK) shares fell -1.18% in last trading session and ended the day at $43.67. BK has a return on assets of 0.90%. The Bank of New York Mellon Corporation (NYSE:BK) quarterly performance is -1.85%.
Bank of New York Mellon Corp (NYSE:BK) has earned an “A” credit rating from Morningstar. The firm’s “A” rating indicates that the company is a low default risk. They also gave their stock a four star rating.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) ended the last trading day at $16.76. Company weekly volatility is calculated as 8.48% and price to cash ratio as 3.72. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) showed a weekly performance of 12.94%.
Bellicum Pharma (NASDAQ: BLCM) reported Q3 EPS of ($0.51), versus $2.08 reported last year. BPX-501 at ASH 2015: Company to present interim data from the BP-004 ongoing Phase 1/2 clinical trial. Bellicum will present initial data in malignant and non-malignant blood diseases at the upcoming 26th Annual Meeting of the American Society of Hematology in early December in Orlando, Florida. The open label dose escalation trial in pediatric patients is evaluating whether BPX-501 T cells from a haploidentical donor, administered following a T-depleted hematopoietic stem cell transplant (HSCT), are safe and can enhance immune reconstitution.
On 09 November, Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) shares remains unchanged and was closed at $1.19. OCLS EPS growth in last 5 year was 19.50%. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) year to date (YTD) performance is -16.78%.
On 5 November, Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) reported Total revenue was $4.1 million for the second quarter, an increase of 24%, when compared to $3.3 million for the same period in 2014. Product revenues were up 64% from the same period last year, led by increases in the United States dermatology market and the rest of world.
Lion Biotechnologies, Inc. (NASDAQ:LBIO) shares fell -0.97% in last trading session and ended the day at $7.12. LBIO has a return on assets of -26.60%. Lion Biotechnologies, Inc. (NASDAQ:LBIO) quarterly performance is 2.45%.
Lion Biotechnologies, Inc. (NASDAQ:LBIO), announced that it has entered into a two-year agreement with WuXi AppTec, Inc. (“WuXi AppTec”) to provide additional TIL manufacturing capacity. The additional manufacturing capability is expected to become available within the first six months of 2016 at WuXi AppTec’s facility in Philadelphia.
Curis, Inc. (NASDAQ:CRIS) caters to the Healthcare space. Its weekly performance is 21.17%. On the last day of trading company shares ended up at $2.69. Curis, Inc. (NASDAQ:CRIS) distance from 50-day simple moving average (SMA50) is 9.85%.
Curis Inc. (NASDAQ:CRIS) reported a net loss of $5.5 million, or ($0.04) per share on both a basic and fully diluted basis for the third quarter of 2015, as compared to a net loss of $5.6 million, or ($0.06) per share on both a basic and fully diluted basis for the third quarter of 2014. Curis reported a net loss of $45.5 million, or ($0.37) per share on both a basic and fully diluted basis for the nine months ended September 30, 2015, as compared to a net loss of $13.0 million, or ($0.15) per share on both a basic and fully diluted basis for the nine months ended September 30, 2014.
Leave a Reply